In part three of this discussion with Charley Hooper, FDA expert and former NASA official, they examine the legacy of FDA’s its “white hat” reputation and how it’s not as deserved as it once was. In addition, they discuss the chilling effect new legislation will have on new cancer treatments, as well as the punitive effect this will have on generic drugs, patients in need of drugs for rare disorders, and testing already approved drugs to combat other diseases.